{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:11:56Z","timestamp":1794557516807,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-00906"],"award-info":[{"award-number":["2016-00906"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2017-0383"],"award-info":[{"award-number":["2017-0383"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011898","name":"Marianne and Marcus Wallenberg Foundation","doi-asserted-by":"publisher","award":["2015.0125"],"award-info":[{"award-number":["2015.0125"]}],"id":[{"id":"10.13039\/501100011898","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alzheimerfonden, Sweden","award":["AF-939932 and AF-930655"],"award-info":[{"award-number":["AF-939932 and AF-930655"]}]},{"name":"Alzheimerfonden, Sweden","award":["AF-939932 and AF-930655"],"award-info":[{"award-number":["AF-939932 and AF-930655"]}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","award":["FO2019-0326 and FO2019-0029"],"award-info":[{"award-number":["FO2019-0326 and FO2019-0029"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","award":["FO2019-0326 and FO2019-0029"],"award-info":[{"award-number":["FO2019-0326 and FO2019-0029"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Parkinson foundation of Sweden","award":["1280\/20"],"award-info":[{"award-number":["1280\/20"]}]},{"name":"Parkinson foundation of Sweden","award":["1280\/20"],"award-info":[{"award-number":["1280\/20"]}]},{"name":"Sk\u00e5ne University Hospital Foundation","award":["2020-O000028"],"award-info":[{"award-number":["2020-O000028"]}]},{"name":"Sk\u00e5ne University Hospital Foundation","award":["2020-O000028"],"award-info":[{"award-number":["2020-O000028"]}]},{"name":"Regionalt Forskningsst\u00f6d","award":["2020-0314"],"award-info":[{"award-number":["2020-0314"]}]},{"name":"Regionalt Forskningsst\u00f6d","award":["2020-0314"],"award-info":[{"award-number":["2020-0314"]}]},{"name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Bundy Academy, and the Swedish federal government under the ALF agreement","award":["2018-Projekt0279"],"award-info":[{"award-number":["2018-Projekt0279"]}]},{"name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Bundy Academy, and the Swedish federal government under the ALF agreement","award":["2018-Projekt0279"],"award-info":[{"award-number":["2018-Projekt0279"]}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cognitive decline in early-stage Alzheimer\u2019s disease (AD) may depend on genetic variability. In the Swedish BioFINDER study, we used polygenic scores (PGS) (for AD, intelligence, and educational attainment) to predict longitudinal cognitive change (measured by mini-mental state examination (MMSE) [primary outcome] and other cognitive tests) over a mean of 4.2\u00a0years. We included 260 \u03b2-amyloid (A\u03b2) negative cognitively unimpaired (CU) individuals, 121 A\u03b2-positive CU (preclinical AD), 50 A\u03b2-negative mild cognitive impairment (MCI) patients, and 127 A\u03b2-positive MCI patients (prodromal AD). Statistical significance was determined at Bonferroni corrected <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.05. The PGS for intelligence (beta\u2009=\u20090.1, <jats:italic>p<\/jats:italic>\u2009=\u20092.9e\u221202) was protective against decline in MMSE in CU and MCI participants regardless of A\u03b2 status. The polygenic risk score for AD (beta\u2009=\u2009\u2009\u2212\u20090.12, <jats:italic>p<\/jats:italic>\u2009=\u20099.4e\u221203) was correlated with the rate of change in MMSE and was partially mediated by A\u03b2-pathology (mediation effect 20%). There was no effect of education PGS on cognitive measures. Genetic variants associated with intelligence mitigate cognitive decline independent of A\u03b2-pathology, while effects of genetic variants associated with AD are partly mediated by A\u03b2-pathology.<\/jats:p>","DOI":"10.1038\/s41598-021-99310-z","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:09:47Z","timestamp":1633651787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Atul","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shoai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"issue":"4","key":"99310_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00002093-200210000-00005","volume":"16","author":"A Perrault","year":"2002","unstructured":"Perrault, A., Wolfson, C., Egan, M., Rockwood, K. & Hogan, D. B. Prognostic factors for functional independence in older adults with mild dementia: Results from the Canadian study of health and aging. Alzheimer Dis. Assoc. Disord. 16(4), 239\u2013247 (2002).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"2","key":"99310_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/ageing\/32.2.200","volume":"32","author":"C Holmes","year":"2003","unstructured":"Holmes, C. & Lovestone, S. Long-term cognitive and functional decline in late onset Alzheimer\u2019s disease: therapeutic implications. Age Ageing 32(2), 200\u2013204 (2003).","journal-title":"Age Ageing"},{"key":"99310_CR3","first-page":"405","volume":"34","author":"J Corey-Bloom","year":"2000","unstructured":"Corey-Bloom, J. & Fleisher, A. S. The natural history of Alzheimer\u2019s disease. Dementia 34, 405\u2013415 (2000).","journal-title":"Dementia"},{"issue":"2","key":"99310_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1192\/bjp.180.2.131","volume":"180","author":"C Holmes","year":"2002","unstructured":"Holmes, C. Genotype and phenotype in Alzheimer\u2019s disease. Br. J. Psychiatry 180(2), 131\u2013134 (2002).","journal-title":"Br. J. Psychiatry"},{"key":"99310_CR5","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/j.neurobiolaging.2019.02.022","volume":"84","author":"MT Lo","year":"2019","unstructured":"Lo, M. T. et al. Alzheimer\u2019s disease genetics consortium. Identification of genetic heterogeneity of Alzheimer\u2019s disease across age. Neurobiol. Aging 84, 2431 (2019).","journal-title":"Neurobiol. Aging"},{"issue":"5","key":"99310_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/jnnp.2004.039321","volume":"76","author":"C Holmes","year":"2005","unstructured":"Holmes, C. et al. Rate of progression of cognitive decline in Alzheimer\u2019s disease: Effect of butyrylcholinesterase K gene variation. J. Neurol. Neurosurg. Psychiatry 76(5), 640\u2013643 (2005).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"99310_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3390\/ijms20051177","volume":"20","author":"J Fan","year":"2019","unstructured":"Fan, J. et al. The contribution of genetic factors to cognitive impairment and dementia: Apolipoprotein E gene, gene interactions, and polygenic risk. Int. J. Mol. Sci. 20(5), 1177 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"99310_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/genes11050501","volume":"11","author":"J Euesden","year":"2020","unstructured":"Euesden, J. et al. Cognitive decline in Alzheimer\u2019s disease: Limited clinical utility for GWAS or polygenic risk scores in a clinical trial setting. Genes 11(5), 501 (2020).","journal-title":"Genes"},{"issue":"1","key":"99310_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3233\/JAD-2010-1255","volume":"19","author":"C Reitz","year":"2010","unstructured":"Reitz, C. & Mayeux, R. Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia. J. Alzheimer\u2019s Dis. 19(1), 229\u2013251 (2010).","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"4","key":"99310_CR10","doi-asserted-by":"publisher","first-page":"P228","DOI":"10.1093\/geronb\/58.4.P228","volume":"58","author":"L B\u00e4ckman","year":"2003","unstructured":"B\u00e4ckman, L., Jones, S., Small, B. J., Ag\u00fcero-Torres, H. & Fratiglioni, L. Rate of cognitive decline in preclinical Alzheimer\u2019s disease: The role of comorbidity. J. Gerontol. B Psychol. Sci. Soc. Sci. 58(4), P228\u2013P236 (2003).","journal-title":"J. Gerontol. B Psychol. Sci. Soc. Sci."},{"key":"99310_CR11","first-page":"86","volume":"8","author":"E Lee","year":"2017","unstructured":"Lee, E. et al. Alzheimer\u2019s disease neuroimaging initiative. Single-nucleotide polymorphisms are associated with cognitive decline at Alzheimer\u2019s disease conversion within mild cognitive impairment patients. Alzheimer\u2019s Dementia Diagn. Assess. Dis. Monit. 8, 86\u201395 (2017).","journal-title":"Alzheimer\u2019s Dementia Diagn. Assess. Dis. Monit."},{"issue":"3","key":"99310_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat. Genet. 51(3), 414\u2013430 (2019).","journal-title":"Nat. Genet."},{"issue":"7","key":"99310_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41588-018-0152-6","volume":"50","author":"JE Savage","year":"2018","unstructured":"Savage, J. E. et al. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nat. Genet. 50(7), 912\u2013919 (2018).","journal-title":"Nat. Genet."},{"issue":"8","key":"99310_CR14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41588-018-0147-3","volume":"50","author":"JJ Lee","year":"2018","unstructured":"Lee, J. J. et al. Gene discovery and polygenic prediction from a 1.1-million-person GWAS of educational attainment. Nature Genet. 50(8), 1112 (2018).","journal-title":"Nature Genet."},{"issue":"9","key":"99310_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","volume":"19","author":"A Torkamani","year":"2018","unstructured":"Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic risk scores. Nat. Rev. Genet. 19(9), 581\u2013590 (2018).","journal-title":"Nat. Rev. Genet."},{"issue":"5","key":"99310_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.tig.2019.02.005","volume":"35","author":"D Chasioti","year":"2019","unstructured":"Chasioti, D., Yan, J., Nho, K. & Saykin, A. J. Progress in polygenic composite scores in Alzheimer\u2019s and other complex diseases. Trends Genet. 35(5), 371\u2013382 (2019).","journal-title":"Trends Genet."},{"issue":"2","key":"99310_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.biopsych.2018.12.015","volume":"86","author":"AR Martin","year":"2019","unstructured":"Martin, A. R., Daly, M. J., Robinson, E. B., Hyman, S. E. & Neale, B. M. Predicting polygenic risk of psychiatric disorders. Biol. Psychiat. 86(2), 97\u2013109 (2019).","journal-title":"Biol. Psychiat."},{"issue":"1","key":"99310_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms10918","volume":"7","author":"N Mattsson","year":"2016","unstructured":"Mattsson, N. et al. Increased amyloidogenic APP processing in APOE \u025b4-negative individuals with cerebral \u03b2-amyloidosis. Nat. Commun. 7(1), 1\u20137 (2016).","journal-title":"Nat. Commun."},{"issue":"11","key":"99310_CR19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele, R. et al. Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320(11), 1151\u20131162 (2018).","journal-title":"JAMA"},{"issue":"4","key":"99310_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 14(4), 535\u2013562 (2018).","journal-title":"Alzheimer\u2019s Dement."},{"issue":"3","key":"99310_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12(3), 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"99310_CR22","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer\u2019s disease. Am. J. Psychiatry. 141, 1356\u20131364 (1984).","journal-title":"Am. J. Psychiatry."},{"issue":"1","key":"99310_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/02813432.2012.751699","volume":"31","author":"AS Kvitting","year":"2013","unstructured":"Kvitting, A. S., Wimo, A., Johansson, M. M. & Marcusson, J. A Quick test of cognitive speed (AQT): Usefulness in dementia evaluations in primary care. Scand. J. Prim. Health Care 31(1), 13\u201319 (2013).","journal-title":"Scand. J. Prim. Health Care"},{"issue":"4","key":"99310_CR24","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","volume":"93","author":"PS Insel","year":"2019","unstructured":"Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93(4), e322\u2013e333 (2019).","journal-title":"Neurology"},{"issue":"22","key":"99310_CR25","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"MC Donohue","year":"2017","unstructured":"Donohue, M. C. et al. Alzheimer\u2019s Disease Neuroimaging Initiative. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 317(22), 2305\u20132316 (2017).","journal-title":"JAMA"},{"issue":"9","key":"99310_CR26","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/nprot.2010.116","volume":"5","author":"CA Anderson","year":"2010","unstructured":"Anderson, C. A. et al. Data quality control in genetic case-control association studies. Nat. Protoc. 5(9), 1564\u20131573 (2010).","journal-title":"Nat. Protoc."},{"issue":"1","key":"99310_CR27","doi-asserted-by":"publisher","first-page":"s13742","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang, C. C. et al. Second-generation PLINK: Rising to the challenge of larger and richer datasets. Gigascience 4(1), s13742\u2013s14015 (2015).","journal-title":"Gigascience"},{"issue":"3","key":"99310_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze, S. et al. Swedish BioFinder Study Group. CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: Better diagnostic markers of Alzheimer disease. Ann. Clin. Transla. Neurol. 3(3), 154\u2013165 (2016).","journal-title":"Ann. Clin. Transla. Neurol."},{"issue":"1","key":"99310_CR29","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s12859-018-2533-3","volume":"19","author":"M Pomaznoy","year":"2018","unstructured":"Pomaznoy, M., Ha, B. & Peters, B. GOnet: A tool for interactive Gene Ontology analysis. BMC Bioinform. 19(1), 470 (2018).","journal-title":"BMC Bioinform."},{"issue":"D1","key":"99310_CR30","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: Protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47(D1), D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"99310_CR31","first-page":"D498","volume":"48","author":"B Jassal","year":"2020","unstructured":"Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48(D1), D498-503 (2020).","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"99310_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat. Rev. Neurol. 9(2), 106\u2013118 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"99310_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamaneurol.2020.3780","volume":"78","author":"PS Insel","year":"2021","unstructured":"Insel, P. S., Hansson, O. & Mattsson-Carlgren, N. Association between apolipoprotein E \u03b52 vs \u03b54, age, and \u03b2-amyloid in adults without cognitive impairment. JAMA Neurol. 78, 229\u2013235 (2021).","journal-title":"JAMA Neurol."},{"issue":"18","key":"99310_CR34","doi-asserted-by":"publisher","first-page":"e1605-12","DOI":"10.1212\/WNL.0000000000005415","volume":"90","author":"T Ge","year":"2018","unstructured":"Ge, T., Sabuncu, M. R., Smoller, J. W., Sperling, R. A. & Mormino, E. C. Alzheimer\u2019s disease neuroimaging initiative dissociable influences of APOE \u03b54 and polygenic risk of AD dementia on amyloid and cognition. Neurology 90(18), e1605-12 (2018).","journal-title":"Neurology"},{"issue":"3","key":"99310_CR35","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3233\/JAD-180713","volume":"66","author":"T Porter","year":"2018","unstructured":"Porter, T. et al. Utility of an Alzheimer\u2019s Disease risk-weighted polygenic risk score for predicting rates of cognitive decline in preclinical alzheimer\u2019s disease: A prospective longitudinal study. J. Alzheimer\u2019s Dis. 66(3), 1193\u20131211 (2018).","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"10","key":"99310_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3389\/fnagi.2018.00423","volume":"19","author":"T Porter","year":"2018","unstructured":"Porter, T. et al. A polygenic risk score derived from episodic memory weighted genetic variants is associated with cognitive decline in preclinical Alzheimer\u2019s disease. Front. Aging Neurosci. 19(10), 423 (2018).","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"99310_CR37","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/ana.25029","volume":"82","author":"CH Tan","year":"2017","unstructured":"Tan, C. H. et al. Polygenic hazard scores in preclinical Alzheimer disease. Ann. Neurol. 82(3), 484\u2013488 (2017).","journal-title":"Ann. Neurol."},{"issue":"3","key":"99310_CR38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41380-018-0030-8","volume":"24","author":"MW Logue","year":"2019","unstructured":"Logue, M. W. et al. Use of an Alzheimer\u2019s disease polygenic risk score to identify mild cognitive impairment in adults in their 50s. Mol. Psychiatry 24(3), 421\u2013430 (2019).","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"99310_CR39","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamaneurol.2017.0244","volume":"74","author":"P Vemuri","year":"2017","unstructured":"Vemuri, P. et al. Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals. JAMA Neurol. 74(6), 718\u2013726 (2017).","journal-title":"JAMA Neurol."},{"issue":"8","key":"99310_CR40","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1001\/jamaneurol.2014.963","volume":"71","author":"P Vemuri","year":"2014","unstructured":"Vemuri, P. et al. Association of lifetime intellectual enrichment with cognitive decline in the older population. JAMA Neurol. 71(8), 1017\u20131024 (2014).","journal-title":"JAMA Neurol."},{"issue":"12","key":"99310_CR41","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1212\/WNL.0000000000002490","volume":"86","author":"P Vemuri","year":"2016","unstructured":"Vemuri, P. et al. Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study. Neurology 86(12), 1128\u20131135 (2016).","journal-title":"Neurology"},{"issue":"12","key":"99310_CR42","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.jalz.2017.04.003","volume":"13","author":"M Osler","year":"2017","unstructured":"Osler, M., Christensen, G. T., Garde, E., Mortensen, E. L. & Christensen, K. Cognitive ability in young adulthood and risk of dementia in a cohort of Danish men, brothers, and twins. Alzheimer\u2019s Dement 13(12), 1355\u20131363 (2017).","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"99310_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-00934-y","volume":"10","author":"K Kauppi","year":"2020","unstructured":"Kauppi, K., R\u00f6nnlund, M., Adolfsson, A. N., Pudas, S. & Adolfsson, R. Effects of polygenic risk for Alzheimer\u2019s disease on rate of cognitive decline in normal aging. Transl. Psychiatry 10(1), 1\u20138 (2020).","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"99310_CR44","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3233\/JAD-180785","volume":"68","author":"AM Rawlings","year":"2019","unstructured":"Rawlings, A. M. et al. Cognitive reserve in midlife is not associated with amyloid-\u03b2 deposition in late-life. J. Alzheimer\u2019s Dis. 68(2), 517\u2013521 (2019).","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"1","key":"99310_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack, C. R. Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 9(1), 119\u2013128 (2010).","journal-title":"Lancet Neurol."},{"key":"99310_CR46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fnins.2017.00281","volume":"11","author":"PS Insel","year":"2017","unstructured":"Insel, P. S. et al. Alzheimer\u2019s Disease Neuroimaging Initiative. Time to amyloid positivity and preclinical changes in brain metabolism, atrophy, and cognition: evidence for emerging amyloid pathology in Alzheimer\u2019s disease. Front. Neurosci. 11, 281 (2017).","journal-title":"Front. Neurosci."},{"issue":"20","key":"99310_CR47","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1212\/WNL.0000000000002683","volume":"86","author":"PS Insel","year":"2016","unstructured":"Insel, P. S. et al. Alzheimer\u2019s Disease Neuroimaging Initiative. Accelerating rates of cognitive decline and imaging markers associated with \u03b2-amyloid pathology. Neurology 86(20), 1887\u20131896 (2016).","journal-title":"Neurology"},{"issue":"19","key":"99310_CR48","doi-asserted-by":"publisher","first-page":"R858","DOI":"10.1016\/j.cub.2010.08.052","volume":"20","author":"MS Ebert","year":"2010","unstructured":"Ebert, M. S. & Sharp, P. A. Emerging roles for natural microRNA sponges. Curr. Biol. 20(19), R858\u2013R861 (2010).","journal-title":"Curr. Biol."},{"issue":"79","key":"99310_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/B978-0-12-394395-8.00003-7","volume":"1","author":"D Singh","year":"2012","unstructured":"Singh, D., Singh, P. K., Chaudhary, S., Mehla, K. & Kumar, S. Exome sequencing and advances in crop improvement. Adv. Genet. 1(79), 87\u2013121 (2012).","journal-title":"Adv. Genet."},{"issue":"3","key":"99310_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.arr.2009.03.002","volume":"8","author":"F Wu","year":"2009","unstructured":"Wu, F. & Yao, P. J. Clathrin-mediated endocytosis and Alzheimer\u2019s disease: an update. Ageing Res. Rev. 8(3), 147\u2013149 (2009).","journal-title":"Ageing Res. Rev."},{"issue":"3","key":"99310_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/gerona\/glx135","volume":"73","author":"M Alsaqati","year":"2018","unstructured":"Alsaqati, M., Thomas, R. S. & Kidd, E. J. Proteins involved in endocytosis are upregulated by ageing in the normal human brain: Implications for the development of Alzheimer\u2019s disease. J. Gerontol. Ser. A 73(3), 289\u2013298 (2018).","journal-title":"J. Gerontol. Ser. A"},{"issue":"2","key":"99310_CR52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/wsbm.1187","volume":"5","author":"F He","year":"2013","unstructured":"He, F. & Balling, R. The role of regulatory T cells in neurodegenerative diseases. Wiley Interdiscip. Rev. Syst. Biol. Med. 5(2), 153\u2013180 (2013).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"issue":"2","key":"99310_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ajhg.2009.12.006","volume":"86","author":"D Ruano","year":"2010","unstructured":"Ruano, D. et al. Functional gene group analysis reveals a role of synaptic heterotrimeric G proteins in cognitive ability. Am. J. Human Genet. 86(2), 113\u2013125 (2010).","journal-title":"Am. J. Human Genet."},{"issue":"7","key":"99310_CR54","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/mp.2011.139","volume":"17","author":"A Pavlowsky","year":"2012","unstructured":"Pavlowsky, A., Chelly, J. & Billuart, P. Emerging major synaptic signaling pathways involved in intellectual disability. Mol. Psychiatry 17(7), 682\u2013693 (2012).","journal-title":"Mol. Psychiatry"},{"issue":"39","key":"99310_CR55","doi-asserted-by":"publisher","first-page":"12187","DOI":"10.1523\/JNEUROSCI.3156-09.2009","volume":"29","author":"P Taneja","year":"2009","unstructured":"Taneja, P. et al. Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome. J. Neurosci. 29(39), 12187\u201312195 (2009).","journal-title":"J. Neurosci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99310-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99310-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99310-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:23:54Z","timestamp":1670084634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99310-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99310"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99310-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"8 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AK, MS, SP, ES, JH and NMC have no disclosures. OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. He has received consultancy\/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche in the past two years.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19853"}}